FDA Rule: Class II Classification of Prognostic Assessment Software for Mild Cognitive Impairment
Stay ahead in the medical device industry with this targeted course on the FDA’s rule for classifying prognostic assessment software of mild cognitive impairment (MCI) as a class II device. Learn specific compliance steps—premarket notification, clinical performance validation, software documentation, usability studies, and labeling. Gain insights into regulatory obligations, risk mitigation, and the impact of non-compliance. Get the detailed knowledge and actionable guidance needed to streamline 510(k) submissions and maintain lawful market access for innovative neurological software solutions.
In this course you will learn the following:
* Understand the FDA’s rationale for classifying prognostic assessment software of mild cognitive impairment as a class II device.
* Identify the special controls and general controls applicable to this device type.
* Implement the required steps for compliance, including premarket notification, performance validation, software documentation, labeling, and usability assessment.
* Recognize the legal and regulatory consequences of failing to comply with the final rule.
NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.
